Neuroblastoma;Neuroblastoma

Clinical and Translational Oncology

Volumn 7, Issue 3, 2005, Pages 133-145

  Castel, Victoria ^a   Cañete, Adela ^a   Noguera, Rosa ^a   Navarro, Samuel ^a   Oltra, Silvestre ^a  

^a HOSPITAL INFANTIL LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; GENETICS; HUMAN; NEUROBLASTOMA; PROGNOSIS; REVIEW; RISK FACTOR;

FORECASTING; HUMANS; NEUROBLASTOMA; PROGNOSIS; RISK FACTORS;

EID: 22244439885     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02708748     Document Type: Review

References (94)

1. a ed. Philadelphia: JB Lippincott Co; 2002. p. 895-937.
2. Berthold F, Hero B, Kremens B, et al. Neuroblastoma. Current drug therapy recommendation as part of the total treatment approach. Drugs. 2000; 59: 1261-77.
3. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis staging and response to treatment in patients with Neuroblastoma. J Clin Oncol. 1988; 6: 1874-81.
4. Evans AE, D'Anglio GJ, Sather HN, et al. A comparison of four staging systems for localized and regional Neuroblastoma: A report from the Children's Cancer Study Group. J Clin Oncol. 1990; 8: 678-88.
5. Carlsen N LT. Clinical staging of neuroblastoma assessment of the various staging systems in pochedly C (ed) neuroblastoma. Tumor Biology and Therapy. Boca Raton FL CRC 1990; 199-228.
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the International Criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993; 11 (8): 1466-77.
7. Nakawara A, Zaizen Y, Ikeda K, et al. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastoma. Cancer. 1991; 68: 2037-44.
8. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol, 1998; 16: 1265-9.
9. Lisa A, Takeuchi Hachitanda Y, Woods WG, et al. Screening for neuroblastoma in North America preliminary results. A pathology review from the Quebec Project. Cancer. 1995; 76: 2363-71.
10. Woods WG, Tuchman M, Robison LL, et al. A population-based study usefulness of screening for neuroblastoma. Lancet. 1996; 348: 1682-7.
11. Schwab M, Westermann F. Hero B. Neuroblastoma biology and molecular and chromosomal pathology. Lancet Oncol. 2003; 4: 472-80.
12. Squire JA, Thorner PS, Weitzman S, et al. Co-amplification of MYCN and DEAD box gene (DDX) in primary neuroblastoma. Oncogene. 1995; 10: 1417-22.
13. Station LW, Schwab M, Bishop JM. Nucleotide sequence of the human N-myc gene. Proc Nath Acad Sci USA. 1986; 83: 1772-6.
14. Schwab M, Ellison J, Busch M, et al. Enhaced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of Neuroblastoma. Proc Natl Acad Sci USA. 1984; 81: 4940-4.
15. Rubie H, Hartmann O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localised neuroblastoma: results of the French NBL 90 Study. J Clin Oncol. 1997; 15 (3): 1171-82.
16. Noguera R, Cañete A, Pellin A, et al. Mycn gain and Mycn amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet. 2003; 140: 157-61.
17. Caron H, Van Sluis P, Van Roy N, et al. Recurrent 1; 17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination for loss of heterocygosity. Am J Hum Genet. 1994; 55: 341-7.
18. Lastowska M, Coterill S, Pearson ADJ, et al. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. Eur Cancer. 1997; 33: 1627-33.
19. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17 (7): 2264-79.
20. Caron H, Van Sluis P, De Kraker J, et al. Allelic loss of chromosome 1 p as a predictor of unfavourable outcome in patiens with neuroblastoma. N Engl J Med. 1996; 334: 225-30.
21. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984; 73: 405-16.
22. Shimada H, Ambros I, Dehner LP, et al. The International Neuroblastoma Pathology Classification (The Shimada system). Cancer. 1999; 86;364-72.
23. Harber M, Bordow SB, Harber PS, et al. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer. 1997; 33 (12): 2031-6.
24. Norris MD, Bordow SB, Haber PS, et al. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer. 1997; 33 (12): 1911-6.
25. Spitz R, Hero B, Ernestus K, et al. FISH analyses for alterations in chromosomes 1,2,3 and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003; 41 (1): 30-5.
26. London WB, Castleberry RP, Look TA, et al. Evidence for a cut-off higher than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. Advances in Neuroblastoma Research. Eleventh Conference June 2004. Genova. ID 336.1 pag. 52.
27. Mosseri V, Michon J, De Bernardi B, et al. Surgery as only treatment for INSS Stage 2 neuroblastoma without MYCN amplification: final report of an European prospective trial. Advances in Neuroblastoma Research, Paris, France (2002) 43.
28. Pérez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stage I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000; 18 (1): 18-26.
29. Plantaz D, Rubie H, Michon J, et al. The treatment of Neuroblastoma with intra-spinal extension with chemotherapy followed by the surgical removal of residual disease: a prospective study of 42 cases. Cancer. 1996; 78: 311-9.
30. Hayes FA, Green AA, O'Connor DM. Chemotherapeutic management of epidural neuroblastoma. Med Ped Oncol. 1989; 17: 6-8.
31. Hsu LL, Evans AE, D'Angio GJ. Hepatomegaly in neuroblastoma stage 4S: criteria for treatment of the vulnerable neonate. Med Ped Oncol. 1996; 27:521.
32. Katzenstein HM, Bowman L, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy and histology in 110 infants with stage D[S] neuroblastoma: The Pediatric Oncology Group Experience - A Pediatric Oncology Group Study. J Clin Oncol. 1998; 16 (6): 2007-17.
33. Nickerson HJ, Matthay KK, Seeger RC. Favourable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group Study. J Clin Oncol. 2000; 18 (3): 477-86.
34. Muro D, Sanguesa C, Alberto C, et al. Valoración ecográfica de las masas suprarrenales congénitas. Radiología. 1996; 38: 27-32.
35. Souvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period. Cancer. 2000; 94: 2474-80.
36. Granata C, Fagnani AM, Gambini C, et al. Features and outcome of neuroblastoma detected before birth. J Pediatr Sur. 2000; 35: 88-91.
37. West D, Shamberger RC, Macklis RM, et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol. 1993; 11 (1): 84-90.
38. Powis MR, Imeson JD, Holmes SJK. The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group. J Pediatr Surg. 1996; 26: 1119-24.
39. Rubie H, Gerrard M, De Bernardi B, Cañete A, et al. Localized and unresectable neuroblastoma in infants: Excellent outcome with low-dose primary chemotherapy. Advances in neuroblastoma research. Eleventh Conference, June 2004. Genova ID: 258.1 pag. 53.
40. Castel V, Badal MD, Bezanilla JL, et al. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol. 1995; 24: 29-35.
41. Matthay KK, Pérez C, Seeger RC, et al. Successful treatment for stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group Study. J Clin Oncol. 1998; 16 (4): 1256-64.
42. Cheung NK, Kushner BH, La Quaglia MP, et al. Survival form non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers. Eur J Cancer. 1997; 33 (12): 2117-20.
43. Hero B, Simon T, Benz-Bohn G, et al. Incidence and time frame of regression in stage 2 and 3 neuroblastoma. Advances in Neuroblastoma Research, Paris, France 2002; 37.
44. Schmidt MI, Lukens JM, Seeger RC, et al. Biological factors determine prognosis in infants with stage IV Neuroblastoma: a prospective Children's Cancer Group Study. J Clin Oncol. 2000; 18 (6): 1260-8.
45. Minard V, Hartmann O, Peyroulet MC, et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology. Br J Cancer. 2000; 83 (8): 973-9.
46. Hayes FA, Smith EI. Neuroblastoma. En: Principles and practice of pediatric oncology. Pizzo PA, Poplack DG, editors. Philadelphia: JBLippincott; 1989. p. 607-22.
47. Matthay KK, Villablanca JD, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl J Med. 1999; 341: 1165-73.
48. Castel V, Cañete A, Navarro S, et al. Outcome of highrisk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001; 37: 537-42.
49. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002; 24 (8): 613-21.
50. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997; 15 (2): 3433-40.
51. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO [German Pediatric Oncology Society] experience. Klin Padiatr. 1990; 202 (4): 262-9.
52. Bernardi BD, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year of age at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-operative Group for Neuroblastoma. J Clin Oncol. 2003; 21 (8): 1592-601.
53. Castel V, Navajas A, García-Miguel P, et al. Stage IV neuroblastoma in children over 1 year of age: results of a cooperative study using high-dose cisplatin-VM26 and cyclophosphamide-doxorrubicin as initial therapy. Int J Pediatr Hemat Oncol. 1995; 2: 255-62.
54. Tweedle DA, Pinkerton R, Lewis IA, et al. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol. 2001; 36: 239-42.
55. Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 1050-8.
56. Pinkerton RC, Blanc Vicent MMP, Bergeron C, et al. Induction chemotherapy in metastatic neuroblastomadoes dose influence response? A critical review of published data standards, options and recommendations [SOR] project of the National Federation of French Cancer Centres [FNCLCC]. Eur J Cancer. 2000; 36: 1808-15.
57. Castel V, García-Miguel P, Cañete A, et al. Prospective Evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur J Cancer. 1999; (4): 606-11.
58. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group Studies. J Clin Oncol. 1996; 14 (9): 2417-26.
59. Kushner B, Laquaglia M, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994; 12 (12): 2607-13.
60. Cheung NK, Kushner BH, Laquaglia M, et al. N7: a novel multi-modality therapy for high-risk neuroblastoma [NB] in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001; 36 (1): 227-30.
61. Valteau-Couanet D, Michon J, Perel Y, et al. Results of NB97 SFOP protocol in children > 1 year with stage 4 neuroblastoma. Advances in Neuroblastoma Research. Paris, France. 2002; 44.
62. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2004 Nov 15.
63. Matthay KK, Seeger RC, Reynolds P, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer. Group. J Clin Oncol. 1994; 12 (11): 2382-9.
64. Ladenstein R, Phillip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998; 16 (3): 953-65.
65. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem-cell transplantation. Bone Marrow Transplant. 1999; 23: 789-95.
66. Ladenstein R, Poetschger U, Hartmann O, et al. Megatherapy/SCT activity in pediatric solid tumors in Europe. Bone Marrow Transplant. 2000; 25(Suppl 1):71.
67. Villablanca JG, Matthay KK, Swift PS, et al. Phase I trial of etoposide, melphalan and local irradiation [CEM-LI] with purged autologous bone marrow transplantation [ABMT] for children with high risk neuroblastoma. Med Pediatr Oncol. 1999; 33:170.
68. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol. 2000; 18 (24): 4067-76.
69. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001; 19 (6): 1795-801.
70. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol. 2000; 18 (3): 468-76.
71. Saarinen UM, Wikstrom S, Makipernaa A. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. J Clin Oncol. 1996; 14 (10): 2791-802.
72. Reynolds CP, Kane DI, Eihom PA, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clini Biolo Res. 1991; 366: 203-11.
73. Kohler JA, Imeson J, Ellershaw C, et al. A randomised trial of 13-cis-retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer. 2000; 83 (9): 1124-7.
74. Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br J Cancer. 2000; 83 (9): 1121-3.
75. Cheung NK, Kushner B, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998; 16 9: 3053-60.
76. Cheung NK, Guo HF, Cheung I Y. Correlation of antiidiotype network with survival following anti-GD2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Med Pediatr Oncol. 2000; 35: 635-7.
77. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991; 324 (4): 219-26.
78. Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol. 1997; 15 (8): 2807-17.
79. Faulkner LB, Tintori V, Tamburini A, et al. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. J Hematother. 1998; 7 (4): 361-6.
80. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001; 19 (6): 1795-801.
81. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer. 1995; 31A(4): 553-6.
82. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol. 2003; 21 (6): 1087-93.
83. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res. 1998; 4 (11): 2801-5.
84. Cheung IY, Cheung NK. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol. 2001; 36 (1): 210-2.
85. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999; 5 (2): 335-41.
86. Oltra S, Martínez F, Orellana C, et al. Minimal residual disease in neuroblastoma: to GAGE or not to GAGE. Oncol Res. 2004; 14 (6): 291-5.
87. Lambooy LH, Gidding CE, Van Den Heuvel LP, et al. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res. 2003; 9 (2): 812-9.
88. Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem. 2003; 49 (1): 104-12.
89. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res. 2003; 12 (4): 435-42.
90. Oltra S, Martínez F, Orellana C, et al. The Doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma [en prensa]. Diagn Mol. Pathol.
91. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med. 1999; 4384: 336-43.
92. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylduanidine, high dose chemotherapy and immunotherapy pilot study. Eur J Cancer. 1998; 34 (9): 1398-402.
93. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobnezylguanidine in combination with myeloablative chemotherapy and autologous stemcell support for the treatment of neuroblastoma. J Clin Oncol. 2002; 20 (8): 2142-9.
94. 131I-MIBG] therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer. 1999; 81 (8): 1378-84.